XRCC1单核苷酸多态性与鼻咽癌铂类化疗敏感度的相关性

目的 探讨鼻咽癌铂类化疗敏感度与X射线交错互补修复基因1 codon194和codon399单核苷酸多态性的相关性。方法 收集广西医科大学第四附属医院2012年9月1日至2013年12月31日鼻咽部肿物活检确诊为鼻咽癌患者资料，采用限制性片段长度多态性聚合酶链反应技术检测鼻咽癌患者外周血DNA XRCC1 codon194和codon399单核苷酸多态性。顺铂+氟尿嘧啶方案诱导化疗2周期后复查MRI，按照RECIST 1.1标准评价其化疗敏感度，分析单核苷酸多态性（Single nucleotide polymorphism,SNP）与化疗敏感度的关系。结果 XRCC1 codon399 Gln/Gln基因型携带者化疗敏感度为Arg/Arg基因型携带者的3.500倍（P＜0.05）。XRCC1 codon399不含Arg基因型（即Gln/Gln）携带者化疗敏感度为含Arg基因型（Arg/Arg 和 Arg/Gln）携带者的3.274倍，（P＜0.05）。携带XRCC1 codon194各基因型患者化疗敏感度之间差异无明显统计学意义（P＞0.05）。结论 XRCC1 codon399 单核苷酸多态性有可能成为鼻咽癌铂类化疗敏感度的预测因子。

Correlation of DNA Repair Gene XRCC1 Single Nucleotide Polymorphism with Sensitivity of Nasopharyngeal Carcinoma Patients to Platinum Chemotherapy

Objective To explore the correlation of codon194 and codon399 single nucleotide polymorphisms (SNP) of DNA repair gene X-ray repair cross-complementing gene 1(XRCC1) with the sensitivity to platinum chemotherapy in nasopharyngeal carcinoma(NPC)patients. Methods The biopsy specimens were obtained from NPC patients diagnosed by nasopharyngeal endoscopy in The Fourth Affiliated Hospital of Guangxi Medical University from September 1 2012 to December 31 2013. XRCC1 SNP at codon194 and codon399 in NPC patients were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). After 2 periods of PF(cisplatin+5-fluorouracil) induction chemotherapy, MRI was taken to assess the efficacy according to RECIST 1.1 standard, evaluate the relationship between SNP and the sensitivity of chemotherapy in nasopharyngeal cancer patients. Results The patients with XRCC1 codon399 Gln/Gln polymorphisms were 3.500 times as sensitive to the chemotherapy as the patients with Arg/Arg genotype(P<0.05). The patients with XRCC1 codon399 Gln/Gln polymorphisms were 3.274 times as sensitive to the chemotherapy as the patients with (Arg/Arg+Arg/Gln) genotype(P<0.05). The sensitivity to chemotherapy wasn't significant different among the patients with XRCC1 codon194 Arg/Arg, Arg/Trp,Trp/Trp polymorphisms(P>0.05). Conclusion XRCC1 codon399 SNP might be a useful predictive marker in NPC patients treated with cisplatin-based chemotherapy.